Abnormal Cerebral Perfusion Profile in Older Adults with HIV-Associated Neurocognitive Disorder: Discriminative Power of Arterial Spin-Labeling

References

1. 1.↵
   2. Hood JE,
   3. Golden MR,
   4. Hughes JP, et al

   . Projected demographic composition of the United States population of people living with diagnosed HIV. AIDS Care 2017;29:1543–50 doi:10.1080/09540121.2017.1308466 pmid:28395528

   CrossRefPubMed
2. 2.↵
   2. Heaton RK,
   3. Clifford DB,
   4. Franklin DR Jr., et al

   ; CHARTER Group. HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER study. Neurology 2010;75:2087–96 doi:10.1212/WNL.0b013e318200d727 pmid:21135382

   Abstract/FREE Full Text
3. 3.↵
   2. Hasse B,
   3. Ledergerber B,
   4. Furrer H, et al

   ; Swiss HIV Cohort Study. Morbidity and aging in HIV-infected persons: the Swiss HIV cohort study. Clin Infect Dis 2011;53:1130–39 doi:10.1093/cid/cir626 pmid:21998280

   CrossRefPubMed
4. 4.↵
   2. Chow FC

   . HIV infection, vascular disease, and stroke. Semin Neurol 2014;34:35–46 doi:10.1055/s-0034-1372341 pmid:24715487

   CrossRefPubMed
5. 5.↵
   2. Hsue PY,
   3. Deeks SG,
   4. Hunt PW

   . Immunologic basis of cardiovascular disease in HIV-infected adults. J Infect Dis 2012;205(Suppl 3):S375–82 doi:10.1093/infdis/jis200 pmid:22577211

   CrossRefPubMed
6. 6.↵
   2. Silva JN,
   3. Polesskaya O,
   4. Wei HS, et al

   . Chronic central nervous system expression of HIV-1 Tat leads to accelerated rarefaction of neocortical capillaries and loss of red blood cell velocity heterogeneity. Microcirculation 2014;21:664–76 doi:10.1111/micc.12145 pmid:24813724

   CrossRefPubMed
7. 7.↵
   2. Jia P,
   3. Zhao Z,
   4. Hulgan T, et al

   ; CHARTER Study Group. Genome-wide association study of HIV-associated neurocognitive disorder (HAND): a CHARTER group study. Am J Med Genet B Neuropsychiatr Genet 2017;174:413–26 doi:10.1002/ajmg.b.32530 pmid:28447399

   CrossRefPubMed
8. 8.↵
   2. Gelman BB,
   3. Chen T,
   4. Lisinicchia JG, et al

   ; National NeuroAIDS Tissue Consortium. The National NeuroAIDS Tissue Consortium brain gene array: two types of HIV-associated neurocognitive impairment. PLoS One 2012;7:e46178 doi:10.1371/journal.pone.0046178 pmid:23049970

   CrossRefPubMed
9. 9.↵
   2. Gelman BB

   . Neuropathology of HAND with suppressive antiretroviral therapy: encephalitis and neurodegeneration reconsidered. Curr HIV/AIDS Rep 2015;12:272–79 doi:10.1007/s11904-015-0266-8 pmid:25860316

   CrossRefPubMed
10. 10.↵
    2. Nakamoto BK,
    3. Jahanshad N,
    4. McMurtray A, et al

    . Cerebrovascular risk factors and brain microstructural abnormalities on diffusion tensor images in HIV-infected individuals. J Neurovirol 2012;18:303–12 doi:10.1007/s13365-012-0106-1 pmid:22585287

    CrossRefPubMed
11. 11.↵
    2. Watson C,
    3. Busovaca E,
    4. Foley JM, et al

    . White matter hyperintensities correlate to cognition and fiber tract integrity in older adults with HIV. J Neurovirol 2017;23:422–29 doi:10.1007/s13365-016-0509-5 pmid:28101804

    CrossRefPubMed
12. 12.↵
    2. Su T,
    3. Wit FW,
    4. Caan MW, et al

    ; AGEhIV Cohort Study. White matter hyperintensities in relation to cognition in HIV-infected men with sustained suppressed viral load on combination antiretroviral therapy. AIDS 2016;30:2329–39 doi:10.1097/QAD.0000000000001133 pmid:27149087

    CrossRefPubMed
13. 13.↵
    2. Chow FC,
    3. Boscardin WJ,
    4. Mills C, et al

    . Cerebral vasoreactivity is impaired in treated, virally suppressed HIV-infected individuals. AIDS 2016;30:45–55 doi:10.1097/QAD.0000000000000875 pmid:26372478

    CrossRefPubMed
14. 14.↵
    2. Chow FC,
    3. Li Y,
    4. Hu Y, et al

    . Relationship between HIV infection, antiretroviral therapy, inflammatory markers, and cerebrovascular endothelial function among adults in urban China. J Acquir Immune Defic Syndr 2017;74:339–46 doi:10.1097/QAI.0000000000001254 pmid:27875362

    CrossRefPubMed
15. 15.↵
    2. van der Veen PH,
    3. Muller M,
    4. Vincken KL, et al

    ; SMART Study Group. Longitudinal relationship between cerebral small-vessel disease and cerebral blood flow: the second manifestations of arterial disease-magnetic resonance study. Stroke 2015;46:1233–38 doi:10.1161/STROKEAHA.114.008030 pmid:25804924

    Abstract/FREE Full Text
16. 16.↵
    2. Mattsson N,
    3. Tosun D,
    4. Insel PS, et al

    ; Alzheimer's Disease Neuroimaging Initiative. Association of brain amyloid-β with cerebral perfusion and structure in Alzheimer's disease and mild cognitive impairment. Brain 2014;137:1550–61 doi:10.1093/brain/awu043 pmid:24625697

    CrossRefPubMed
17. 17.↵
    2. Tosun D,
    3. Schuff N,
    4. Jagust W, et al

    ; Alzheimer's Disease Neuroimaging Initiative. Discriminative power of arterial spin labeling magnetic resonance imaging and 18F-fluorodeoxyglucose positron emission tomography changes for amyloid-β-positive subjects in the Alzheimer's disease continuum. Neurodegener Dis 2016;16:87–94 doi:10.1159/000439257 pmid:26560336

    CrossRefPubMed
18. 18.↵
    2. Ances BM,
    3. Sisti D,
    4. Vaida F, et al

    ; HNRC group. Resting cerebral blood flow: a potential biomarker of the effects of HIV in the brain. Neurology 2009;73:702–08 doi:10.1212/WNL.0b013e3181b59a97 pmid:19720977

    Abstract/FREE Full Text
19. 19.↵
    2. Su T,
    3. Mutsaerts HJ,
    4. Caan MW, et al

    ; AGEhIV Cohort Study. Cerebral blood flow and cognitive function in HIV-infected men with sustained suppressed viremia on combination antiretroviral therapy. AIDS 2017;31:847–56 doi:10.1097/QAD.0000000000001414 pmid:28121708

    CrossRefPubMed
20. 20.↵
    2. Towgood KJ,
    3. Pitkanen M,
    4. Kulasegaram R, et al

    . Regional cerebral blood flow and FDG uptake in asymptomatic HIV-1 men. Hum Brain Mapp 2013;34:2484–93 doi:10.1002/hbm.22078 pmid:22496057

    CrossRefPubMed
21. 21.↵
    2. Sen S,
    3. An H,
    4. Menezes P, et al

    . Increased cortical cerebral blood flow in asymptomatic human immunodeficiency virus-infected subjects. J Stroke Cerebrovasc Dis 2016;25:1891–95 doi:10.1016/j.jstrokecerebrovasdis.2016.03.045 pmid:27160382

    CrossRefPubMed
22. 22.↵
    2. Clifford KM,
    3. Samboju V,
    4. Cobigo Y, et al

    . Progressive brain atrophy despite persistent viral suppression in HIV patients older than 60 years. J Acquir Immune Defic Syndr 2017;76:289–97 doi:10.1097/QAI.0000000000001489 pmid:28650401

    CrossRefPubMed
23. 23.↵
    2. Antinori A,
    3. Arendt G,
    4. Becker JT, et al

    . Updated research nosology for HIV-associated neurocognitive disorders. Neurology 2007;69:1789–99 doi:10.1212/01.WNL.0000287431.88658.8b pmid:17914061

    Abstract/FREE Full Text
24. 24.↵
    2. Milanini B,
    3. Valcour V

    . Differentiating HIV-associated neurocognitive disorders from Alzheimer's disease: an emerging issue in geriatric NeuroHIV. Curr HIV/AIDS Rep 2017;14:123–32 doi:10.1007/s11904-017-0361-0 pmid:28779301

    CrossRefPubMed
25. 25.↵
    2. Luh WM,
    3. Wong EC,
    4. Bandettini PA, et al

    . QUIPSS II with thin-slice TI1 periodic saturation: a method for improving accuracy of quantitative perfusion imaging using pulsed arterial spin labeling. Magn Reson Med 1999;41:1246–54 pmid:10371458

    CrossRefPubMedWeb of Science
26. 26.↵
    2. Tao R,
    3. Fletcher PT,
    4. Gerber S, et al

    . A variational image-based approach to the correction of susceptibility artifacts in the alignment of diffusion weighted and structural MRI. Inf Process Med Imaging 2009;21:664–75 pmid:19694302

    PubMed
27. 27.↵
    R Development Core Team. R foundation for statistical computing. https://www.r-project.org/.
28. 28.↵
    2. Friedman J,
    3. Hastie T,
    4. Tibshirani R

    . Regularization paths for generalized linear models via coordinate descent. J Stat Softw 2010;33;1–22 pmid:20808728

    CrossRefPubMedWeb of Science
29. 29.↵
    2. van Buuren S,
    3. Groothuis-Oudshoorn K

    . MICE: multivariate imputation by chained equations in R. J Stat Softw 2011;45. https://www.jstatsoft.org/article/view/v045i03.
30. 30.↵
    2. Frigessi A,
    3. Bühlmann P,
    4. Glad IK, et al

    . Statistical Analysis for High-Dimensional Data: The Abel Symposium 2014. New York: Springer; 2016
31. 31.↵
    2. Sanford R,
    3. Fernandez Cruz AL,
    4. Scott SC, et al

    . Regionally specific brain volumetric and cortical thickness changes in HIV-infected patients in the HAART era. J Acquir Immune Defic Syndr 2017;74:563–70 doi:10.1097/QAI.0000000000001294 pmid:28129254

    CrossRefPubMed
32. 32.↵
    2. Kendall CE,
    3. Wong J,
    4. Taljaard M, et al

    . A cross-sectional, population-based study measuring comorbidity among people living with HIV in Ontario. BMC Public Health 2014;14:161 doi:10.1186/1471-2458-14-161 pmid:24524286

    CrossRefPubMed
33. 33.↵
    2. Sheppard DP,
    3. Iudicello JE,
    4. Bondi MW, et al

    . Elevated rates of mild cognitive impairment in HIV disease. J Neurovirol 2015;21:576–84 doi:10.1007/s13365-015-0366-7 pmid:26139019

    CrossRefPubMed
34. 34.↵
    2. Hong S,
    3. Banks WA

    . Role of the immune system in HIV-associated neuroinflammation and neurocognitive implications. Brain Behav Immun 2015;45;1–12 doi:10.1016/j.bbi.2014.10.008 pmid:25449672

    CrossRefPubMed
35. 35.↵
    2. Chow FC,
    3. Regan S,
    4. Zanni MV, et al

    . Elevated ischemic stroke risk among women living with HIV infection. AIDS 2018;32:59–67 doi:10.1097/QAD.0000000000001650 pmid:28926405

    CrossRefPubMed